On February 3, Novartis announced that a new indication for secukinumab (brand name: Cosentyx) had been approved by the NMPA for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs), with objective signs of elevated C-reactive protein (CRP) and/or MRI evidence.
This is secukinumab’s sixth approved indication in China, following adult psoriasis, pediatric psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa.
Secukinumab is the world’s first fully human interleukin-17A (IL-17A) inhibitor to be approved. It specifically neutralizes IL-17A from multiple sources and suppresses its pro-inflammatory effects.
The drug first achieved global approval in Japan on December 26, 2014, followed by approvals in the European Union and the United States in January 2015. It is now approved for moderate to severe plaque psoriasis in adults, ankylosing spondylitis in adults, active psoriatic arthritis in adults, non-radiographic axial spondyloarthritis in adults, moderate to severe pediatric plaque psoriasis in patients aged 6 years and older, psoriatic arthritis in patients aged 2 years and older, enthesitis-related arthritis in patients aged 4 years and older, and hidradenitis suppurativa in adults.
Secukinumab first entered the Chinese market in April 2019 for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. To date, all five previously approved indications in China have entered the National Reimbursement Drug List, and this newly approved use is the sixth.
According to Insight database, secukinumab has completed two Phase III clinical trials in non-radiographic axial spondyloarthritis.
The overseas approval was based on positive results from the Phase III PREVENT study (NCT02696031), although mainland China was not among the study locations. A domestic Phase III study (NCT04732117/CTR20211320) was initiated in early 2021, but its results have not yet been disclosed.
PREVENT is a two-year randomized, double-blind, placebo-controlled Phase III study with a two-year extension designed to evaluate the efficacy and safety of secukinumab in nr-axSpA patients.
The study enrolled 555 adult patients with nr-axSpA with disease onset before age 45, spinal pain VAS score ≥40/100, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4. Before study entry, patients had received the highest dose of at least two NSAIDs for four weeks, or had been treated with up to one TNF inhibitor with inadequate response. A total of 501 patients (90.3%) were biologic-naive.
The primary endpoint was the proportion of TNF-naive patients achieving ASAS40 response at Weeks 16 and 52 with secukinumab 150 mg treatment.
At Week 16, secukinumab 150 mg produced a higher ASAS40 response rate than placebo in nr-axSpA patients (40.0% vs 28.0%, P<0.05), and improvement was sustained to Week 52 with a favorable safety profile. In nr-axSpA patients with inadequate response to NSAIDs, secukinumab significantly and durably improved symptoms and signs and effectively controlled disease progression.
As one of the major blockbusters in autoimmune disease, secukinumab generated USD 1.128 billion in sales as early as 2016 after its first approval in December 2014. Global sales hit a new high of USD 6.141 billion in 2024 and still maintained double-digit growth (+23.31%). This reflects the broad promise of the IL-17A target in autoimmune disease, and secukinumab continued to expand into new indications through the end of 2023.
Competition is also intense. From the biosimilar perspective, Insight database shows that five secukinumab biosimilars are already in clinical development in China alone. The fastest is Bio-Thera’s BAT2306, which filed for marketing in February 2025 and has signed out-licensing deals with four companies for different overseas markets. CSPC’s SYS6012 and Mabwell’s CMAB015 are also already in Phase III development.
From the target perspective, besides secukinumab, four other IL-17A monoclonal antibodies have already been approved in China and six are under review. Among the four approved new drugs, two are from multinational companies—bimekizumab (UCB, IL-17A/F) and ixekizumab (Eli Lilly)—and two are from domestic companies: netakimab (Zhixiang Jintai) and funatizumab (Hengrui Medicine).
Although secukinumab still leads its target class in number of approved indications, it is undoubtedly facing aggressive pursuit by many later entrants.
Axial spondyloarthritis (axSpA) is a long-term inflammatory disease characterized by chronic inflammatory back pain. Its symptom burden includes night pain, fatigue, morning stiffness, and functional disability. If untreated, axSpA can impair mobility, cause lost work time, and significantly affect quality of life, including family relationships.
This new approval of secukinumab will provide a new treatment option for relevant patients.